Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | 212Pb-TCMC-Trastuzumab |
| Trade Name | |
| Synonyms | |
| Drug Descriptions |
212Pb-TCMC-Trastuzumab, a combination of trastuzumab, the chelating agent TCMC, and lead Pb 212, targets and destroys HER2 positive cells through cytotoxic radiation (PMID: 27906723). |
| DrugClasses | HER2 (ERBB2) Antibody 79 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| 212Pb-TCMC-Trastuzumab | 212Pb-TCMC-Trastuzumab | 0 | 0 |
| 212Pb-TCMC-Trastuzumab + Trastuzumab | 212Pb-TCMC-Trastuzumab Trastuzumab | 0 | 1 |